MINNEAPOLIS and ATLANTA, April 16, 2026 /PRNewswire/ -- Francis Medical, Inc., a privately held medical device company, today announced the continued expansion of its U.S. commercial launch with the ...

View post: I Needed a Shoe That Could Handle Sprints and Box Jumps. This Under Armour Pair Was the Standout Winner Prostate cancer often goes undetected early due to lack of symptoms and awareness.

New guidance from several major societies, including the American College of Cardiology (ACC) and American Heart Association (AHA), is now available for operators and institutions looking to start and ...

Pfizer (PFE) announced on Thursday that its cancer drug regimen, Talzenna plus Xtandi, met the primary endpoint in a Phase 3 trial for a new indication in prostate cancer. The Phase 3 TALAPRO-3 study ...

Add Yahoo as a preferred source to see more of our stories on Google. The scan works by using a molecule that binds to prostate cancer cells, causing them to appear as bright spots on imaging A scan ...

These procedures represent the first use of the Vanquish System in routine commercial practice in the state outside of a formal clinical study. Vanquish is a transurethral, ultrasound, and ...

Gov. Kay Ivey has signed into law a bill to require insurance companies to cover prostate cancer screening at no cost for men who are at high risk of the disease. Lawmakers passed the bill last week ...

Hormone blockade therapy, which includes both oral and injectable options, aims to slow or stop the growth of prostate cancer cells by reducing androgen levels. Injectable hormone blockade therapies, ...

Salvage focal therapy may offer durable localized prostate cancer control for up to 10 years compared with salvage radical prostatectomy for radiorecurrent disease. For patients with localized, biopsy ...

ORLANDO, Fla. (Ivanhoe Newswire) - The American Cancer Society reports that about one in eight men will be diagnosed with prostate cancer in their lifetime. The average age of men who get diagnosed is ...

In a population-based cohort study, a single prostate-specific antigen (PSA) measurement in men aged 45-70 years effectively identified individuals with low risk for cancer. Men with PSA levels < 1.00 ...